FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficacy and safety versus chemotherapy in patients with FGFR mRN...

Descripción completa

Detalles Bibliográficos
Autores principales: Sternberg, Cora N., Petrylak, Daniel P., Bellmunt, Joaquim, Nishiyama, Hiroyuki, Necchi, Andrea, Gurney, Howard, Lee, Jae-Lyun, van der Heijden, Michiel S., Rosenbaum, Eli, Penel, Nicolas, Pang, See-Tong, Li, Jian-Ri, García del Muro, Xavier, Joly, Florence, Pápai, Zsuzsanna, Bao, Weichao, Ellinghaus, Peter, Lu, Chengxing, Sierecki, Mitchell, Coppieters, Sabine, Nakajima, Keiko, Ishida, Tatiane Cristine, Quinn, David I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870218/
https://www.ncbi.nlm.nih.gov/pubmed/36240478
http://dx.doi.org/10.1200/JCO.21.02303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870218/
https://www.ncbi.nlm.nih.gov/pubmed/36240478
http://dx.doi.org/10.1200/JCO.21.02303

Ejemplares similares